ONCURIOUS passes European Commission Orphan Medicinal Product designation for TB-403 for medulloblastoma.
M2 PHARMA-January 17, 2017-ONCURIOUS passes European Commission Orphan Medicinal Product designation for TB-403 for medulloblastoma
(C)2017 M2 COMMUNICATIONS
Oncology company ONCURIOUS NV reported on Tuesday the receipt of the European Commission orphan drug designation for TB-403 for medulloblastoma.
The company said TB-403 is a humanized monoclonal antibody against placental growth factor (PlGF). PlGF is expressed in several types of cancer, including medulloblastoma. In medulloblastoma patients, high expression of the PlGF receptor neuropilin 1 has been shown to correlate with poor overall patient survival.
EC approval follows a prior in-depth review and positive opinion on the TB-403 drug candidate by the EMA Committee for Orphan Medicinal Products (COMP).
Currently, TB-403 is being evaluated in a Phase I/IIa clinical trial for treatment of medulloblastoma, a rare life-threatening brain tumor that mainly affects children.
This clinical trial is being conducted in partnership with the Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC). The consortium is a collaboration of 25 US academic medical centres, teaching hospitals and other entities.
In conjunction, ONCURIOUS is working with BioInvent International AB as a development partner for this project.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Date:||Jan 17, 2017|
|Previous Article:||Benitec's BB-301 wins orphan drug designation in the EU for treating oculopharyngeal muscular dystrophy.|
|Next Article:||Philogen granted IND approval by FDA for Phase 3 registration trial with investigational melanoma drug.|